Dutch GMP contract manufacturer of biopharmaceuticals SynCo Bio Partners has expanded its business into a new geographical market with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company.
The undisclosed company's product is an innovative live biotherapeutic-based anticancer drug. The project will first involve a consultancy phase, during which SynCo will assist the client with in-house process development. The developed process will then be transferred to SynCo's Amsterdam facility and scaled up, prior to GMP manufacture for Phase I clinical trials, including fermentation, formulation and aseptic filling.
"We are extremely pleased to be working with our first Japanese partner," commented SynCo's ceo, Pierre Warffemius. "This contract represents SynCo's entry into the growing Japanese biotherapeutics market and is reflective of our continuing success in a very competitive GMP contract manufacturing market."
SynCo is a specialist in the development of manufacturing processes and GMP production of live biotherapeutics and provides a one-stop-shop for the production of both bulk drug substance and final lyophilised product.